Drugs / 177Lu-labeled NY108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05815394 | Mar 2023 → Mar 2024 | prostate cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-labeled NY108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05815394 ↗ |
| Modality | Diagnostic / imaging agent | “177Lu-labeled NY108 (177Lu-NY108) SPECT Imaging” NCT05815394 ↗ |